Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- ALS has a metabolic component: weight loss
- ALS has a metabolic component
- ALS mutations impair energy metabolism
- Outstanding questions
- Weight loss occurs years before onset of motor symptoms
- Weight loss is typically observed in ALS mouse models
- Are weight loss and metabolic abnormalities target for ALS treatment?
- Weight loss predicts survival
- High-calorie diet increases survival of ALS mice
- LIPCAL-ALS
- Summary: ALS progression is related to weight loss
- What are the key cell types driving weight loss in ALS?
- Location of the hypothalamus and its nuclei
- Hypothalamic structural alterations
- Hypothalamic volume is correlated to BMI
- Hypothalamic alterations are mostly found in the LHA
- MCH neurons degenerate in the LHA
- Loss of MCH blunts food intake in mutant SOD1 mice
- Pharmacological strategies?
- Summary and conclusions
- Acknowledgment
Topics Covered
- Amyotrophic Lateral Sclerosis (ALS)
- ALS and weight loss
- Progression of ALS
- High-calorie diet
- Hypothalamus in ALS
- Melanin-concentrating hormone (MCH) neurons
- Relationship between MCH neurons, ALS, and weight loss
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Dupuis, L. (2023, December 31). Importance of nutrition and weight loss in motor neuron disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/VRJZ3110.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Luc Dupuis has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: ALS and Other Motor Neuron Disorders
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome to the talk
on the importance
of nutrition and weight
in amyotrophic lateral
sclerosis motor neuron disease.
I have a PhD and
working as an Inserm
research director
in Strasbourg, France.
0:17
Why do we say that weight
loss is important in ALS?
Because ALS has actually
a component that is
related to metabolism.
Weight loss in ALS is
caused by multiple factors,
but two of these are actually
the most important ones.
One is decreased food intake,
which is particularly
related to dysphasia
that occurs during
disease progression
and the other one
is increased energy expenditure-
both of them might be
related to altered
hypothalamic signaling.
I hope that in this talk
I will convince you that the
hypothalamus is actually
instrumental in weight loss in
ALS patients and that
dietary intervention and
in particular high caloric,
high-fat diet might
be important in terms of
therapeutic counseling.
1:14
Another component of ALS is
related to energy metabolism
and is actually systemic.
There are pathological
abnormalities in ALS tissues
beyond the classical origins of
the CNS that are involved in ALS.
For instance, the
hypothalamus is atrophied,
there are TDP-43 aggregates,
especially in the lateral
hypothalamic area,
and there are impairments of
various hypothalamic signaling,
including melanocortin.
In the pancreas,
there have been reports of
impaired insulin secretion.
In the adipose tissue,
the tissue has been
atrophied and is abnormally
distributed as compared
to healthy controls.
Skeletal muscle shows
increased lipid usage,
impaired glucose usage, and
mitochondrial dysfunction.